Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma after Donor-Derived CD7- Chimeric Antigen Receptor T-Cell Therapy
Blood(2021)
Abstract
Background: In our phase I clinical trial, 90% complete remission (CR) in r/r T-ALL/LBL has been achieved with donor-derived CD7-chimeric antigen receptor T-cell (CART) therapy (Pan J. et al. JCO July 29, 2021 online), but hematopoiesis and immune reconstitution is crucial for long-term disease-free survival (DFS) in this setting.
MoreTranslated text
Key words
leukemia/lymphoma,leukemia/lymphoma,t-cell,donor-derived,t-cell
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined